Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Cancer|October 30, 2024
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYXEduardo Rodríguez-Arbolí, Rebeca Rodríguez-Veiga, Elena Soria-Saldise, et al.
Blood Advances|February 9, 2021
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Bruno Paiva, David Martínez-Cuadrón, et al.
Cancer|April 24, 2019
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA GroupJosep-Maria Ribera, Olga García, María-José Moreno, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Leukemia Research|March 14, 2022
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registryJuan-Carlos Hernández-Boluda, David Martínez-Cuadrón, Arturo Pereira, et al.
Leukemia Research|November 24, 2018
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patientsDavid Martínez-Cuadrón, Cristina Gil, Josefina Serrano, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2019
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid LeukemiaJuan Eduardo Megías-Vericat, David Martínez-Cuadrón, Joaquín Martínez López, et al.
Cancers|September 13, 2025
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA StudyAntonio Solana-Altabella, Irene Navarro-Vicente, Eduardo Rodríguez-Arbolí, et al.
Cancers|December 17, 2024
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA GroupsSusana Vives, David Quintela, Mireia Morgades, et al.
Pageof 9